|
Travere Therapeutics Inc (NASDAQ: TVTX) |
|
Travere Therapeutics Inc
TVTX's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Travere Therapeutics Inc growth rates, revenue grew
by 97.54 % in the first quarter of 2025 from the same quarter a year ago.
Ranking at No. 1403
Major Pharmaceutical Preparations industry recorded
growth of revenues by 3.97 %
Travere Therapeutics Inc net loss decreased from $-136 millions, to $-41 millions in first quarter of 2025,
• More on TVTX's Growth
|
|
Travere Therapeutics Inc realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 99.23 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 6.76.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.11.
• More on TVTX's Valuation
|
|
|
|
|
Travere Therapeutics Inc realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 99.23 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 6.76.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.11.
Travere Therapeutics Inc Price to Book Ratio is at 56.37 lower than Industry Avg. of 76.67. and higher than S&P 500 Avg. of 0.01
• More on TVTX's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com